ALB and esophageal squamous cell carcinoma: In general, based on the preliminary findings of this study, PD-1 inhibitors combined with albumin-bound paclitaxel + cisplatin, with a high conversion surgery rate, pCR rate, R0 resection rate and long-term survival rate, are more suitable for induction therapy before conversion therapy for cT4b ESCC than is chemotherapy alone.